Orchid Cellmark's Q4 Revenues Rise 21 Percent on Forensics Testing Services | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Orchid Cellmark today reported fourth-quarter revenue growth of 21 percent, driven by its forensic testing services in the UK and US.

The Princeton, NJ-based firm had total revenues of $15.7 million for the three-month period ended Dec. 31, compared to $13 million for the fourth quarter of 2008. Its service revenues rose to $14.9 million from $13 million year over year, led by forensic testing in the UK and US, the firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.